Moderna, Inc. vs Zillow Group Inc Class C — how do they compare? Moderna, Inc. trades at $64.17 (market cap $24.18B), while Zillow Group Inc Class C trades at $33.09 (market cap $7.68B). The key difference: Moderna, Inc. is far larger — about 3.1× Zillow Group Inc Class C's market cap, and Moderna, Inc. is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| MRNA | Z | |
|---|---|---|
Market Cap | $24.18B | $7.68B |
Sector | Health | Media |
52-Week High | $81.80 | $90.35 |
52-Week Low | $22.36 | $29.41 |
Enterprise Value | $20.33B | $7.56B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.
The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →